Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort®

MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

UNAUDITED FINANCIAL INFORMATION OF SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026

Set out below is the key unaudited financial information of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("**Endovastec**") for the nine months ended 30 September 2026. Endovastec is owned as to 40.32% by the Group and its results are consolidated with the financial statements of the Company. The shares of Endovastec are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

	For the nine months ended 30 September 2026 ***RMB'000***	For the nine months ended 30 September 2025 *RMB'000*	Change *%*
Revenue	**1,118,935.32**	1,014,780.04	10.26
Profit before tax	**517,270.60**	497,543.03	3.96
Net profit attributable to equity owners of Endovastec	**448,565.93**	429,055.90	4.55

	As of 30 September 2026 ***RMB'000***	As of 31 December 2025 *RMB'000*	Change *%*
Total assets	**5,037,099.75**	4,641,152.08	8.53
Total equity attributable to equity owners of Endovastec	**4,220,057.48**	4,075,341.12	3.55

Shareholders and investors of the Company are reminded that the financial information of Endovastec above was prepared in accordance with PRC accounting standards and is limited solely to the operation of Endovastec and is unrelated to the other subsidiaries of the Group. Such information is unaudited, and does not (a) exclude intra-group transactions, (b) include all the business of the Group, and (c) represent or provide a full picture of the operation or status of the Group.

SUSPENSION OF TRADING

Pursuant to Rule 13.50 of the Listing Rules, the Stock Exchange will normally require suspension of trading in an issuer's securities if an issuer fails to publish periodic financial information in accordance with the Listing Rules, and the suspension will normally remain in force until the issuer publishes an announcement containing the requisite financial information.

At the request of the Company, trading in the shares of the Company on the Stock Exchange (stock code: 853) and its debt securities (debt stock code: 40168) was suspended from 9:00 a.m. on 1 September 2026, pending the publication of the 2026 Interim Results. Further announcement(s) will be made by the Company as and when appropriate and in compliance with the requirements under the Listing Rules.

Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
MicroPort Scientific Corporation
Mr. Jonathan W. Chen
Executive Director

Shanghai, the PRC, 29 October 2026

As at the date of this announcement, the executive Director is Mr. Jonathan W. Chen; the non-executive Directors are Dr. Feng Gu, Ms. Jing Huang and Ms. Weiqin Sun; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu, Mr. Chunyang Shao and Dr. Yingyao Chen.

* *For identification purpose only*